For adult periodontitis. ANDA 210537, held by Alembic. Doxycycline Hyclate.
As of Nov 16, 2026, ANDA 210537 (Doxycycline Hyclate), held by Alembic, was first approved by FDA on Mar 4, 2020, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Doxycycline hyclate tablets are indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 4, 2020 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxycycline HyclateEQ 20MG BASE · tablet;oral | Doxycycline Hyclate | Rx |
| Mar 31, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Mar 4, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters